{"title":"日本的肌肉疏松性肥胖诊断:日本肌肉疏松性肥胖症工作组共识声明","authors":"Kojiro Ishii, Wataru Ogawa, Yutaka Kimura, Toru Kusakabe, Ryo Miyazaki, Kiyoshi Sanada, Noriko Satoh-Asahara, Yuki Someya, Yoshifumi Tamura, Kohjiro Ueki, Hidetaka Wakabayashi, Yuya Watanabe, Minoru Yamada, Hidenori Arai","doi":"10.1111/ggi.14978","DOIUrl":null,"url":null,"abstract":"<p>Sarcopenic obesity is the co-existence of obesity and sarcopenia in individuals aged 40–75 years. The Japanese Working Group on Sarcopenic Obesity has developed diagnostic criteria tailored for the Japanese population, considering their unique characteristics compared with European populations. Our algorithm consists of two steps: screening and diagnosis. The screening of obesity mandates using waist circumference and/or body mass index (BMI) based on national standards, while screening for sarcopenia involves the “finger ring test” in addition to the Asian Working Group for Sarcopenia 2019 criteria. The final diagnosis of sarcopenia involves handgrip strength for low muscle strength, the five-times chair stand test for low physical function, and limb skeletal muscle mass (corrected for BMI) for low muscle mass. Obesity is assessed by visceral fat area or body fat percentage. Sarcopenic obesity is then categorized into Stage I, with muscle weakness/loss of function, loss of muscle mass, and obesity; or Stage II, which includes complications. Further clinical validation is needed to refine the consensus and age range. <b>Geriatr Gerontol Int 2024; 24: 997–1000</b>.</p>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ggi.14978","citationCount":"0","resultStr":"{\"title\":\"Diagnosis of sarcopenic obesity in Japan: Consensus statement of the Japanese Working Group on Sarcopenic Obesity\",\"authors\":\"Kojiro Ishii, Wataru Ogawa, Yutaka Kimura, Toru Kusakabe, Ryo Miyazaki, Kiyoshi Sanada, Noriko Satoh-Asahara, Yuki Someya, Yoshifumi Tamura, Kohjiro Ueki, Hidetaka Wakabayashi, Yuya Watanabe, Minoru Yamada, Hidenori Arai\",\"doi\":\"10.1111/ggi.14978\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Sarcopenic obesity is the co-existence of obesity and sarcopenia in individuals aged 40–75 years. The Japanese Working Group on Sarcopenic Obesity has developed diagnostic criteria tailored for the Japanese population, considering their unique characteristics compared with European populations. Our algorithm consists of two steps: screening and diagnosis. The screening of obesity mandates using waist circumference and/or body mass index (BMI) based on national standards, while screening for sarcopenia involves the “finger ring test” in addition to the Asian Working Group for Sarcopenia 2019 criteria. The final diagnosis of sarcopenia involves handgrip strength for low muscle strength, the five-times chair stand test for low physical function, and limb skeletal muscle mass (corrected for BMI) for low muscle mass. Obesity is assessed by visceral fat area or body fat percentage. Sarcopenic obesity is then categorized into Stage I, with muscle weakness/loss of function, loss of muscle mass, and obesity; or Stage II, which includes complications. Further clinical validation is needed to refine the consensus and age range. <b>Geriatr Gerontol Int 2024; 24: 997–1000</b>.</p>\",\"PeriodicalId\":2,\"journal\":{\"name\":\"ACS Applied Bio Materials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2024-09-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ggi.14978\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Applied Bio Materials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/ggi.14978\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MATERIALS SCIENCE, BIOMATERIALS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ggi.14978","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
引用次数: 0
摘要
肌肉疏松性肥胖症是指 40-75 岁的人同时患有肥胖症和肌肉疏松症。日本肌少症肥胖症工作组考虑到日本人与欧洲人相比的独特性,为日本人量身定制了诊断标准。我们的算法包括两个步骤:筛查和诊断。筛查肥胖症必须使用基于国家标准的腰围和/或体重指数(BMI),而筛查肌肉疏松症除了使用 2019 年亚洲肌肉疏松症工作组标准外,还包括 "指环测试"。肌肉疏松症的最终诊断涉及低肌力的手握力、低身体功能的五次椅子站立测试和低肌肉质量的四肢骨骼肌质量(根据体重指数校正)。肥胖症通过内脏脂肪面积或身体脂肪百分比进行评估。然后将肌无力型肥胖分为第一阶段(肌肉无力/功能丧失、肌肉质量下降和肥胖)和第二阶段(包括并发症)。需要进一步的临床验证来完善共识和年龄范围。Geriatr Gerontol Int 2024; --:-----.
Diagnosis of sarcopenic obesity in Japan: Consensus statement of the Japanese Working Group on Sarcopenic Obesity
Sarcopenic obesity is the co-existence of obesity and sarcopenia in individuals aged 40–75 years. The Japanese Working Group on Sarcopenic Obesity has developed diagnostic criteria tailored for the Japanese population, considering their unique characteristics compared with European populations. Our algorithm consists of two steps: screening and diagnosis. The screening of obesity mandates using waist circumference and/or body mass index (BMI) based on national standards, while screening for sarcopenia involves the “finger ring test” in addition to the Asian Working Group for Sarcopenia 2019 criteria. The final diagnosis of sarcopenia involves handgrip strength for low muscle strength, the five-times chair stand test for low physical function, and limb skeletal muscle mass (corrected for BMI) for low muscle mass. Obesity is assessed by visceral fat area or body fat percentage. Sarcopenic obesity is then categorized into Stage I, with muscle weakness/loss of function, loss of muscle mass, and obesity; or Stage II, which includes complications. Further clinical validation is needed to refine the consensus and age range. Geriatr Gerontol Int 2024; 24: 997–1000.